TherapeuticsMD (NASDAQ:TXMD – Get Free Report) is expected to issue its Q3 2026 resultson Tuesday, November 17th. Analysts expect TherapeuticsMD to announce earnings of ($6.1250) per share and revenue of $19.77 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. The firm had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $19.77 million. TherapeuticsMD had a negative net margin of 6.64% and a negative return on equity of 1.09%.
TherapeuticsMD Trading Down 2.9%
Shares of NASDAQ:TXMD opened at $1.69 on Tuesday. The company has a market cap of $19.55 million, a price-to-earnings ratio of 84.50 and a beta of 0.68. The company has a 50-day moving average price of $2.00 and a 200-day moving average price of $2.10. TherapeuticsMD has a 12 month low of $1.29 and a 12 month high of $2.95.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, TherapeuticsMD currently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on TXMD
TherapeuticsMD Company Profile
TherapeuticsMD, Inc was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States.
The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.
Further Reading
- Five stocks we like better than TherapeuticsMD
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
